Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain

References

• Grandjenette C, Dicato M, Diederich M. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells. Curr Pharm Biotechnol 2015; 16:670-683; PMID:25941884; http://dx.doi.org/10.2174/1389201016666150505124037
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4944; PMID:19509221; http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
   PubMed Web of Science ®Google Scholar
• Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672-692; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
   PubMed Web of Science ®Google Scholar
• Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu XQ, Leow CC, Gibson N, Wilson S, Stover CK, Wu H, Gao C, Dimasi N. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs. 2016; PMID:27981887
   Web of Science ®Google Scholar
• Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000; 165:5112-5121; PMID:11046042; http://dx.doi.org/10.4049/jimmunol.165.9.5112
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Rossi EA, Chang CH, Cardillo TM, Goldenberg DM. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjugate Chem 2013; 24:63-71; PMID:23116517; http://dx.doi.org/10.1021/bc300488f
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-6171; PMID:19372261; http://dx.doi.org/10.1182/blood-2008-10-187138
   PubMed Web of Science ®Google Scholar
• Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potenttumor inhibition. Arch Biochem Biophys 2012; 526:206-218; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
   PubMed Web of Science ®Google Scholar
• Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013; 26:187-193; PMID:23175797; http://dx.doi.org/10.1093/protein/gzs096
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. MAbs 2016; 8:969-982; PMID:27111637; http://dx.doi.org/10.1080/19420862.2016.1178435
   PubMed Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 6:653-63; PMID:22925968;http://dx.doi.org/10.4161/mabs.21379
   Web of Science ®Google Scholar
• Strop P, F Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-219; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-5150; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 8:753-758; PMID:23831709;http://dx.doi.org/10.1038/nbt.2621
   Web of Science ®Google Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11-16; PMID:15903235; http://dx.doi.org/10.1021/bp040016j
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-1413; PMID:17727329; http://dx.doi.org/10.1517/14712598.7.9.1401
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239-1249; PMID:15037082; http://dx.doi.org/10.1016/j.jmb.2004.01.007
   PubMed Web of Science ®Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37:697-706; PMID:11275255; http://dx.doi.org/10.1016/S0161-5890(00)00105-X
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. The structural role of antibody N-Glycosylation in receptor interactions. Structure 2015; 23:1573-1583; PMID:26211613; http://dx.doi.org/10.1016/j.str.2015.06.015
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-198; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108:11187-11192; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
   PubMed Web of Science ®Google Scholar
• Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 2015; 6:6113; PMID:25672245; http://dx.doi.org/10.1038/ncomms7113
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-1614; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 2015; 7:377-389; PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816
   PubMed Web of Science ®Google Scholar
• Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290:7535-7562; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
   PubMed Web of Science ®Google Scholar
• Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, et al. XGFR, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. MAbs 2016; 4:811-827; PMID:26984378; http://dx.doi.org/10.1080/19420862.2016.1160989
   Web of Science ®Google Scholar
• Lee HS, Shu L, De Pascalis R, Giuliano M, Zhu M, Padlan EA, Hand PH, Schlom J, Hong HJ, Kashmiri SV. Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol 1999; 36:61-71; PMID:10369421; http://dx.doi.org/10.1016/S0161-5890(98)00109-6
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Menzel C, Hust M, Prilop J, Jostock T, Dübel S. Oligomeric forms of single chain immunoglobulin (scIgG). MAbs 2010; 1:73-76; PMID:20081378; http://dx.doi.org/10.4161/mabs.2.1.10784
   Google Scholar
• Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M, Kirsch MI, Meier D, Dübel S. Single chain Fab (scFab) fragment. BMC Biotechnol 2007; 7:14; PMID:17346344; http://dx.doi.org/10.1186/1472-6750-7-14
   PubMed Web of Science ®Google Scholar
• Koerber JT, Hornsby MJ, Wells JA. An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol 2015; 427:576-586; PMID:25481745; http://dx.doi.org/10.1016/j.jmb.2014.11.017
   PubMed Web of Science ®Google Scholar
• Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 2012; 40:W288-93; PMID:22581768; http://dx.doi.org/10.1093/nar/gks419
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Ginestoux C, Bodmer J, Müller W, Bontrop R, Lemaitre M, Malik A, Barbié V, Chaume D. IMGT, the international ImMunoGeneTics database. Nucl Acids Res 1999; 1:209-212; PMID:9847182; http://dx.doi.org/10.1093/nar/27.1.209
   Web of Science ®Google Scholar
• Swindells MB, Porter CT, Couch M, Hurst J, Abhinandan KR, Nielsen JH, Macindoe G, Hetherington J, Martin AC. abYsis: integrated antibody sequence and structure-management, analysis, and prediction. J Mol Biol 2016; in press; PMID:27561707
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-288; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Hou JJC, Hughes BS, Smede M, Leung KM, Levine K, Rigby S, Gray PP, Munro TP. High-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system. New Biotechnol 2014; 31:214-220; PMID:24518824; http://dx.doi.org/10.1016/j.nbt.2014.02.002
   PubMed Web of Science ®Google Scholar
• Sandercock AM, Rust S, Guillard S, Sachsenmeier KF, Holoweckyj N, Hay C, Flynn M, Huang Q, Yan K, Herpers B, et al. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling. Mol Cancer 2014; 14:147; PMID:26227951; http://dx.doi.org/10.1186/s12943-015-0415-0
   Web of Science ®Google Scholar
• Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J Mol Biol 1990; 211:943-958; PMID:2313701; http://dx.doi.org/10.1016/0022-2836(90)90085-Z
   PubMed Web of Science ®Google Scholar
• George R, Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 2002; 15:871-879; PMID:12538906; http://dx.doi.org/10.1093/protein/15.11.871
   PubMedGoogle Scholar
• Chen X, Zaro J, Shen WC. Fusion protein linkers: Property, design and functionality. Adv Drug Deliv Rev 2013; 65:1357-1369; PMID:23026637; http://dx.doi.org/10.1016/j.addr.2012.09.039
   PubMed Web of Science ®Google Scholar
• Shen Y, Zeng L, Zhu A, Blanc T, Patel D, Pennello A, Bari A, Ng S, Persaud K, Kang YK, et al. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity. MAbs 2013; 5:418-431; PMID:23567210; http://dx.doi.org/10.4161/mabs.24291
   PubMed Web of Science ®Google Scholar
• Liu H, Zhong S, Chumsae C, Radziejewski C, Hsieh CM. Effect of the light chain C-terminal serine residue on disulfide bond susceptibility of human immunoglobulin G1λ. Anal Biochem 2011; 408:277-283; PMID:20869344; http://dx.doi.org/10.1016/j.ab.2010.09.025
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-2324; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750-1755; PMID:19250681; http://dx.doi.org/10.1016/j.molimm.2009.01.026
   PubMed Web of Science ®Google Scholar
• Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, et al. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics. J Control Release 2016; 236:100-116; PMID:27327768; http://dx.doi.org/10.1016/j.jconrel.2016.06.025
   PubMed Web of Science ®Google Scholar
• Prasad GL, Lee HS, Iwahashi M, Milenic DE, Abrams S, Schlom J, Kashmiri SV. In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response. Cancer Gene Ther 1997; 4:253-259; PMID:9253511
   PubMed Web of Science ®Google Scholar